138 related articles for article (PubMed ID: 17166367)
1. [Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2].
Zhou JJ; Chen RF; Tang QB; Zhou QB; Lu HW; Wang J
Ai Zheng; 2006 Dec; 25(12):1459-63. PubMed ID: 17166367
[TBL] [Abstract][Full Text] [Related]
2. [Preparation of doxorubicin encapsulated in amphiphilic polysaccharide nanoparticles and anti-hepatocarcinoma effect thereof].
Huang YF; Gu WL; Li ZH; Chen RF; Zhou JJ; Zhou QB; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):810-2. PubMed ID: 19595118
[TBL] [Abstract][Full Text] [Related]
3. [Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo].
Li S; Jiang WQ; Wang AX; Guan ZZ; Pan SR
Ai Zheng; 2004 Apr; 23(4):381-5. PubMed ID: 15087023
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
[TBL] [Abstract][Full Text] [Related]
5. Polymeric nanoparticles for oral delivery of 5-fluorouracil: Formulation optimization, cytotoxicity assay and pre-clinical pharmacokinetics study.
Mattos AC; Altmeyer C; Tominaga TT; Khalil NM; Mainardes RM
Eur J Pharm Sci; 2016 Mar; 84():83-91. PubMed ID: 26775869
[TBL] [Abstract][Full Text] [Related]
6. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
Xu DB; Wang YL; Yue Y; Wu SC; Ding H
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
[TBL] [Abstract][Full Text] [Related]
8. [In vitro release study, in vivo evaluation of biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates].
Yuan F; Zhang ZR; Yang YX; Huang Y
Yao Xue Xue Bao; 2008 Nov; 43(11):1152-6. PubMed ID: 19239037
[TBL] [Abstract][Full Text] [Related]
9. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
10. SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.
Ma X; Cheng Z; Jin Y; Liang X; Yang X; Dai Z; Tian J
Biomaterials; 2014 Mar; 35(9):2878-89. PubMed ID: 24411331
[TBL] [Abstract][Full Text] [Related]
11. [Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles].
Huang KH; Liu JH; Wang LY; Zhu ZH; Chen QK; Min J; Chen RF
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):482-5. PubMed ID: 17851795
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Li S; Wang A; Jiang W; Guan Z
BMC Cancer; 2008 Apr; 8():103. PubMed ID: 18412945
[TBL] [Abstract][Full Text] [Related]
13. [Preparation and release efficiency of polylactic acid nanoparticle].
Huang KH; Zhu ZH; Liu JH; Chen QK; Liu XY; Chang J
Ai Zheng; 2005 Aug; 24(8):1023-6. PubMed ID: 16086887
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Gong C; Wang C; Wang Y; Wu Q; Zhang D; Luo F; Qian Z
Nanoscale; 2012 May; 4(10):3095-104. PubMed ID: 22535210
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.
Jin Y; Li J; Rong LF; Li YH; Guo L; Xu SY
World J Gastroenterol; 2005 May; 11(17):2643-6. PubMed ID: 15849826
[TBL] [Abstract][Full Text] [Related]
16. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
17. Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil.
Al Sabbagh C; Tsapis N; Novell A; Calleja-Gonzalez P; Escoffre JM; Bouakaz A; Chacun H; Denis S; Vergnaud J; Gueutin C; Fattal E
Pharm Res; 2015 May; 32(5):1585-603. PubMed ID: 25416027
[TBL] [Abstract][Full Text] [Related]
18. Preparation of 5-fluorouracil-loaded nanoparticles and study of interaction with gastric cancer cells.
Fan YL; Fan BY; Li Q; Di HX; Meng XY; Ling N
Asian Pac J Cancer Prev; 2014; 15(18):7611-5. PubMed ID: 25292036
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Cao LQ; Shao ZL; Peng HP; Xiao JB; Xia T
Chin J Cancer; 2010 Aug; 29(8):741-6. PubMed ID: 20663321
[TBL] [Abstract][Full Text] [Related]
20. The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
Liu J; Qi S; Zhu H; Zhang J; Li Z; Wang T
Chin Med J (Engl); 2002 May; 115(5):759-62. PubMed ID: 12133551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
